Advanced Therapies Europe

From September 5^th to 7^th, more than 600 cell and gene therapy industry experts are gathering in Lisbon to explore opportunities, discover the latest innovations, and connect with others on the same mission tackling the challenges of advanced therapies in Europe.

The topic tracks about "manufacturing, supply chain, and logistics", "patient perspectives and priorities", "investing in innovation", "developing the therapeutics of the future", "automation" and "commercialization of next generation advanced therapies" spark innovative thinking and discussions.

One panel discussion covers the topic of "The EU health technology assessment regulations: pricing and reimbursement opportunities of novel therapeutics in Europe". Dr. Lydia Frick, manager market access at SKC consulting, shares her knowledge on the future design of the EU-wide joint clinical assessment (JCA) as a panelist and is looking forward to an inspiring conversation with

• Paolo Morgese, Head of Public Affairs, Europe, Alliance for Regenerative Medicine
• Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
• Thomas Bols, Head of Government Affairs and Patient Advocacy, EMEA, PTC Therapeutics and
• Åse Rosenqvist, Nordic Business Unit Lead Cell Therapy, Janssen.

Are you also participating in this event? Please get in touch with us for a personal meeting.